Topiramate Tablet, Film Coated
Product Images NDC 60760-577

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 60760-577). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Top (Topiramate 60760 577 60)

Label for Topiramate 50 mg oral film-coated tablets by St. Mary's Medical Park Pharmacy. The label shows the proprietary and nonproprietary name, strength 50 mg, quantity 60 tablets, and prescription-only status. It includes barcodes, a GS1 data matrix, and manufacturing details by Cadila Healthcare Ltd., India. The label instructs to store at controlled room temperature 15°-30°C (59°-86°F).*

FDA Label Image

Structured Product Formula For Topiramate (A9eed983 Edf1 4f44 A8ec 568a52f03015 01)

Chemical structure diagram of the active ingredient topiramate, showing its molecular framework with labeled functional groups and stereochemistry.*

FDA Label Image

Structured Product Formula For Topiramate (A9eed983 Edf1 4f44 A8ec 568a52f03015 02)

A Kaplan-Meier plot showing cumulative rates for time to first seizure over approximately 500 days for two dosing groups of topiramate: 50 mg/day (solid line) and 400 mg/day (dashed line). The y-axis represents cumulative rates for time to first seizure, and the x-axis represents time in days. The chart includes a statistical significance annotation (P = 0.0002).*

FDA Label Image

Topiramate Tablets Usp (A9eed983 Edf1 4f44 A8ec 568a52f03015 03)

A bar chart comparing the change from baseline to double-blind phase in average monthly migraine period rate (± standard error) for placebo and topiramate at doses of 50 mg/day, 100 mg/day, and 200 mg/day. Data from two studies (Study 10 and Study 11) are shown, with decreasing migraine rates noted as dosage increases. Statistical significance is indicated with asterisks below the bars.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.